NCT06772246View on ClinicalTrials.gov

A Study to Evaluate QTc Prolongation With Quizartinib in Healthy Subjects Under Rapid Acceleration of Heart Rate

PHASE1CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

October 24, 2024

Primary Completion Date

June 12, 2025

Study Completion Date

June 12, 2025

Conditions
Healthy Subjects
Interventions
DRUG

Quizartinib

Participants will receive a single oral dose of 90 mg

OTHER

Placebo

Participants will receive a single oral dose of 90 mg

Trial Locations (1)

78217

WCT, San Antonio

Sponsors

Lead Sponsor

Daiichi Sankyo
All Listed Sponsors
lead

Daiichi Sankyo

INDUSTRY

NCT06772246 - A Study to Evaluate QTc Prolongation With Quizartinib in Healthy Subjects Under Rapid Acceleration of Heart Rate | Biotech Hunter | Biotech Hunter